Scynexis (SCYX) Return on Capital Employed (2014 - 2026)
Scynexis (SCYX) posted Return on Capital Employed of 46.51% for Q1 2026, down 42.86% on a QoQ basis from 32.56% in Q4 2025, and up 500.0% year-over-year from 7.75% in Q1 2025.
Scynexis (SCYX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Scynexis' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 46.51% for Q1 2026.
- Quarterly Return on Capital Employed rose 500.0% year-over-year to 46.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46.51% (up 500.0% YoY) and the FY2025 annual result came in at 23.26%, up 2019.0% from the prior year.
- Return on Capital Employed was 46.51% for Q1 2026 at Scynexis, down from 32.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 76.93% in Q1 2024 and bottomed at 229.58% in Q1 2023.
- A 5-year average of 44.82% and a median of 59.12% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 15272 bps — and 2024, when it soared 30652 bps.
- Scynexis' Return on Capital Employed stood at 104.03% in 2022, then jumped by 157 bps to 59.48% in 2023, then slumped by 188 bps to 52.47% in 2024, then soared by 38 bps to 32.56% in 2025, then plunged by 43 bps to 46.51% in 2026.
- Business Quant data shows SCYX's Return on Capital Employed at 46.51% in Q1 2026, 32.56% in Q4 2025, and 73.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 21.43% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 5.24% |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - | -46.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.51% |
| Dec 31, 2025 | -32.56% |
| Sep 30, 2025 | -73.04% |
| Jun 30, 2025 | -68.38% |
| Mar 31, 2025 | -51.51% |
| Dec 31, 2024 | -52.47% |
| Sep 30, 2024 | -67.09% |
| Jun 30, 2024 | -59.12% |
| Mar 31, 2024 | 76.93% |
| Dec 31, 2023 | 59.48% |
| Sep 30, 2023 | 54.30% |
| Jun 30, 2023 | 63.84% |
| Mar 31, 2023 | -229.58% |
| Dec 31, 2022 | -104.03% |
| Sep 30, 2022 | -78.02% |
| Jun 30, 2022 | -77.35% |
| Mar 31, 2022 | -76.87% |
| Dec 31, 2021 | -60.09% |
| Sep 30, 2021 | -52.68% |
| Jun 30, 2021 | -50.65% |